CAJ | 학술논문

内皮祖细胞(endothelial progenitor cells,EPCs)是造血干细胞一支骨髓衍生群.目前EPCs的鉴定是结合多方面的综合鉴定.在慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)中,低氧刺激、正常迁移的趋化因子增加、外周循环过度消耗、反应性凋亡、营养缺乏,以及炎症因子刺激等综合因素导致EPCs数量改变,最终使组织修复能力和血管再生能力耗竭.干/祖细胞治疗在COPD中拥有一定的运用前景,其移植过程中的安全性评估意义重大.
내피조세포(endothelial progenitor cells,EPCs)시조혈간세포일지골수연생군.목전EPCs적감정시결합다방면적종합감정.재만성조새성폐질병(chronic obstructive pulmonary disease,COPD)중,저양자격、정상천이적추화인자증가、외주순배과도소모、반응성조망、영양결핍,이급염증인자자격등종합인소도치EPCs수량개변,최종사조직수복능력화혈관재생능력모갈.간/조세포치료재COPD중옹유일정적운용전경,기이식과정중적안전성평고의의중대.
Endothelial progenitor cells(EPCs) are bone marrow-derived hematopoietic stem cells.Now the identification of EPCs is multi-disciplinary identification.In chronic obstructive pulmonary disease(COPD),hypoxia stimulation,chenmokine increasing,over-consumption,reactive apoptosis,nutritional deficiencies,and inflammatory cytokines lead to the changes in the number of EPCs,finally tissue repair capacity and blood vessel regeneration exhaust.Stem/progenitor cell therapy in COPD has a bright prospect.The safety assessment in transplantation is significant.